Treatment limited small-cell lung cancer concurrent etoposide/cisplatin radiotherapy intensification high-dose cyclophosphamide Southwest Oncology Group study March May Southwest Oncology Group untreated patients limited small-cell lung cancer treatment program high-dose cyclophosphamide mg/kg late intensification Treatment induction chemo-radiotherapy weeks consolidation chemotherapy weeks intensification week Median age years Eighty-nine percent patients Southwest Oncology Group SWOG performance status patients prescribed treatments treatment-related deaths result intensification Fifty-six patients available response analysis Thirty-two patients complete remission CR fifteen partial remission PR Median survival patients months patients intensification alive CR median survival months sequence treatments survival advantage group whole toxicity induction consolidation treatment delayed administration high-dose cyclophosphamide 